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Abstract
Background: Glioblastoma multiforme (GBM) is a rapidly growing malignant brain tumor, which has been reported
to be organized in a hierarchical fashion with cancer stem cells (CSCs) at the apex. Recent studies demonstrate that
this hierarchy does not follow a one-way route but can be reverted with more differentiated cells giving rise to cells
possessing CSC features. We investigated the role of tumor microvascular endothelial cells (tMVECs) in reverting
differentiated glioblastoma cells to CSC-like cells.
Methods: We made use of primary GBM lines and tMVECs. To ensure differentiation, CSC-enriched cultures were
forced into differentiation using several stimuli and cultures consisting solely of differentiated cells were obtained
by sorting on the oligodendrocyte marker O4. Reversion to the CSC state was assessed phenotypically by CSC
marker expression and functionally by evaluating clonogenic and multilineage differentiation potential.
Results: Conditioned medium of tMVECs was able to replenish the CSC pool by phenotypically and functionally
reverting differentiated GBM cells to the CSC state. Basic fibroblast growth factor (bFGF), secreted by tMVECs,
recapitulated the effects of the conditioned medium in inducing re-expression of CSC markers and increasing
neurosphere formation ability of differentiated GBM cells.
Conclusions: Our findings demonstrate that the CSC-based hierarchy displays a high level of plasticity showing
that differentiated GBM cells can acquire CSC features when placed in the right environment. These results point
to the need to intersect the elaborate network of tMVECs and GBM CSCs for efficient elimination of GBM CSCs.
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Background
Glioblastoma multiforme (GBM) is a nearly universally le-
thal, heterogeneous primary brain tumor. Despite aggressive
treatment comprising surgical resection, radiotherapy, and
temozolomide (TMZ) chemotherapy, the prognosis of GBM
remains dismal with a 5-year survival rate of only 10 % [1].
After treatment, recurrence is almost inevitable and is
thought to be driven by cancer stem cells (CSCs). CSCs are
suggested to be the only cells within a malignancy able to
drive tumor growth and progression. Moreover, they have
been shown to resist most cancer therapies and are therefore
held responsible for poor clinical outcome [2–4].
The CSC hypothesis suggests that tumors follow a
hierarchical organization with CSCs localizing at the
apex and giving rise to all differentiated progeny that
can be found in the malignancy. However, several stud-
ies have challenged this concept indicating that the dif-
ferentiation of CSCs is not a one-way route but might be
a reversible process that can be directed by signals from
the tumor microenvironment [5–7]. It should be noted
that the dynamic conversion between differentiation
states could be, at least in part, an intrinsic feature. A
model of this stochastic interconversion was reported by
Gupta and colleagues for breast cancer [8] and was also
shown in melanoma [9]. As for GBM, CSCs can be gen-
erated by progenitor cells in response to microenviron-
mental signals [10–12]. Two recent studies showed that
non-stem glioblastoma cells can convert to CSC-like
cells upon therapeutic stress, such as TMZ treatment or
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ionizing radiation [13, 14]. These results demonstrate
that stochastic transition between distinct differenti-
ation states - as has been described before for breast
cancer - also occurs in GBM [8, 13, 15, 16]. Differenti-
ated cells were defined by the downregulation of CSC
markers and the increased expression of differentiation
markers; however, the selection of these cells was not
based on proteins flagging the differentiation state. In
case of a cell sorting-based approach, differentiated
cells were defined by the absence of CSC markers. This
approach does not exclude the existence of concealed
CSCs not expressing the classical CSC markers which
could expand upon treatment.
In this study, we assessed the role of the GBM CSC
niche consisting of tumor microvascular endothelial
cells (tMVECs) in regulating cell fate. Conditioned
medium of tMVECs was sufficient to phenotypically
and functionally revert differentiated cancer cells to the
CSC state. To avoid the presence of cryptic CSCs, we
forced primary GBM spheroid cultured cells to differ-
entiate to distinct lineages by multiple differentiation
techniques. Additionally, with the use of the cell surface
marker O4, we sorted differentiated oligodendrocytes
from the total population and therefore excluded the
presence of CSCs devoid of traditional CSC markers.
O4-expressing differentiated GBM cells were able to
convert to CSC-like cells, showing that differentiated
cancer cells could acquire CSC features.
Results
tMVECs increase self-renewal capacity and CD133 expres-
sion of CD133− GBM cells
Populations expressing high levels of CD133 were shown
to be enriched for CSCs in a wide variety of malignan-
cies, including GBM [17, 18]. Although it is questionable
whether CD133 identifies the CSC population in all
GBM tumors, [19–22] its usefulness to identify cells that
possess the capacity to self-renew, to spawn all differen-
tiated progeny, and to serially propagate tumors has
been well-documented in several primary spheroid cul-
tured GBM lines [17, 18]. We therefore examined the
expression of CD133 in three primary GBM lines, G073,
G062, and G408. As described before, such GBM spher-
oid cultures displayed a gradient of CD133 expression
and the highest CD133 expressing cells (top 10 %,
CD133+) were endowed with high self-renewal capability
determined by clonogenic assays [17, 23]. In contrast,
the clonogenicity of cells expressing no or low levels of
CD133 (lowest 10 %, CD133-) was lower, indicating their
more differentiated character (Fig. 1a and Additional file
1: Figure S2B). Although these CD133− cells had a lower
capacity to self-renew and be clonogenic, conditioned
medium derived from tMVECs (endothelial cell condi-
tioned medium, ECCM) was capable of conveying such
CSC features to these non-stem GBM cells. When plated
in ECCM, the self-renewal ability of CD133− cells in-
creased to a similar clonogenic potential as the one of
CD133+ cells (Fig. 1a and Additional file 1: Figure S2B),
suggesting that factors present in ECCM induce self-
renewal in initially poorly clonogenic cells.
To address the question whether this effect is also ob-
served when employing other CSC markers, we made
use of the G073 spheroid culture, which expresses a gra-
dient of stage-specific embryonic antigen 1 (SSEA-1), a
cell surface marker that has been reported to identify
GBM CSCs [24]. The low clonogenic potential of
SSEA-1− cells in control medium strongly increased
when these cells were plated in ECCM (Additional file
1: Figure S2A), indicating that the ECCM effect is not
specific for CD133.
We speculated that the 2 week time frame of clonogenic
assays might leave possible small numbers of contaminating
CD133+ cells in the sorted CD133− fraction enough time to
proliferate and grow out, potentially misjudging the effect
of ECCM as reversion of CD133− cells instead of outgrowth
of CD133+ cells. To address this point, CD133− cells were
sorted in control medium or ECCM and CD133 expression
was analyzed 24 or 72 h after sorting, giving no time for
possible contaminating CD133+ cells to grow out. ECCM
was able to increase expression of CD133 in the initially
negative population already 24 or 72 h after plating (Fig. 1b
and c and Additional file 1: Figure S2C).
The above-described effects could also be observed
when CD133− G062 cells were plated in conditioned
medium derived from human umbilical vein endothelial
cells (HUVECs; HUVEC conditioned medium, HCM)
(Additional file 1: Figure S2D and S2E).
Thus, tumor-derived as well as normal tissue endothe-
lial cells are capable of phenotypically and functionally
reverting non-stem GBM cells to the CSC state.
tMVECs induce CD133 expression in differentiated GBM
cells
Although CD133− cells are considered to comprise the
more differentiated part of a GBM spheroid culture, they
are not differentiated and can thus contain a subpopula-
tion of cells that still maintain self-renewal and sphere
forming activity. Therefore, in order to determine the ef-
fect of ECCM on differentiated tumor cells, we forced in
vitro differentiation of GBM CSCs toward the neuronal
and astrocytic lineages using bone morphogenetic pro-
tein 4 (BMP4) [25]. After 7 days of BMP4 treatment, the
G073 and G062 primary GBM lines displayed glial
fibrillary acidic protein (GFAP) expression. G073 cells
also induced βIII-tubulin expression and downregulated
the CSC marker SSEA-1 (Fig. 2a and Additional file 1:
Figure S3A). Quantitative real-time PCR (qRT PCR)
results confirmed the increased expression of these
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differentiation markers and revealed the downregulation
of the CSC marker OLIG2 in both cultures and of Musa-
shi1 in G073 cells (Fig. 2b). In addition, CD133 and Nestin
expression were strongly reduced on BMP4-treated GBM
cells (Fig. 2c and Additional file 1: Figure S3B).
Even though GBM cells were almost completely de-
void of CD133 upon BMP4 treatment, we sorted
CD133− cells to avoid the presence of cells expressing
low levels of this CSC marker. Differentiated, CD133−
cancer cells were sorted into control medium or ECCM
Fig. 1 ECCM increases the clonogenic potential and CD133 expression of CD133− GBM cells. a Indicated is the clonogenic potential of the CD133−
fraction of G073 (left) and G062 (right) cultures in control medium or ECCM and of CD133+ cells in control medium, scored 2 weeks after sorting
(n≥ 3). b, c G073 (b) and G062 (c) CD133− cells were plated in control medium or ECCM directly after sorting. Quantification and FACS profiles
depict CD133 expression 24 h (G073) or 72 h (G062) after sorting (n = 3)
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and CD133 expression was reanalyzed after 5 days revealing
that cells plated in ECCM significantly induced CD133 ex-
pression (Fig. 2d). BMP4-differentiated CD133− G073 and
G062 cells were plated in clonogenic assays to address the
functional conversion of these differentiated cells to the
CSC state. Indeed, the clonogenic potential of these cells
Fig. 2 Differentiation of GBM CSCs using BMP4 leads to upregulation of differentiation markers and downregulation of the CSC marker CD133
which is reversed by ECCM. a BMP4 induces upregulation of the astrocyte marker GFAP in G073 (left) and G062 (right) cells and induction of the
neuronal marker βIII-tubulin in G073 cells as compared to cells plated in CSC medium + GFs (scale bars 20 μm). b-d Upper panels: G073, lower
panels: G062. b Differentiation markers are upregulated and CSC markers are downregulated upon BMP4 treatment compared to cells plated in
CSC medium + GFs as determined by qRT PCR (1 representative of 3 independent experiments is shown) and c the CSC marker CD133 is not de-
tectable anymore (n > 3). d BMP4-differentiated CD133− cells were sorted and plated in either control medium or ECCM. 5 days after sorting
CD133 expression was reanalyzed by FACS (n≥ 4)
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increased when plated in ECCM compared to control
medium (Additional file 1: Figure S3C).
Hence, based on marker expression and on clono-
genic capacity, ECCM is capable of reverting BMP4-
differentiated cells to the CSC state.
bFGF secreted by tMVECs induces the reversion of
differentiated GBM cells
We performed a growth factor array on ECCM to iden-
tify which factors secreted by tMVECs could be respon-
sible for the reversion. This revealed a wide range of
growth factors (GFs) that could potentially be involved
in reversal of differentiated GBM cells to the CSC state
(Fig. 3a and Additional file 1: Figure S4A). We focused
on bFGF, epidermal growth factor (EGF), hepatocyte
growth factor (HGF), and vascular endothelial growth
factor (VEGF) in further experiments, since bFGF and
EGF play an important role in GBM CSC maintenance,
[26, 27] HGF was shown to revert differentiated colorec-
tal cancer cells to a CSC phenotype, [5] and VEGF was
described to promote viability of GBM CSCs [28].
To assess which factor could be responsible for induc-
tion of CD133 expression, BMP4-differentiated CD133−
G073 cells were sorted and plated in control medium,
medium containing bFGF, EGF, HGF, or VEGF. Analysis
of CD133 expression 5 days after plating unveiled that
only bFGF significantly increased the amount of CD133-
expressing cells (Fig. 3b). Moreover, when G062 cells
were induced to differentiate with BMP4, stimulation of
the resulting CD133− cells with bFGF also significantly
re-induced CD133 expression, indicating that the rever-
sion was observed in other primary cultures as well
(Additional file 1: Figure S4B). The observed effect of
bFGF on induction of CD133 expression was not con-
centration dependent, as 10, 50, and 100 ng/ml yielded
comparable results (Fig. 3c and Additional file 1: Figure
S4B). Additionally, EGF, HGF, and VEGF were not able
to induce CD133 expression even when used at very
high doses (100 ng/ml, Fig. 3c).
To prove that bFGF present in the conditioned
medium was responsible for the ECCM-induced rever-
sion we made use of a bFGF neutralizing antibody
(bFGF nAb). Addition of this antibody to ECCM pre-
vented the induction of CD133 expression in BMP4-
differentiated G073 cells (Fig. 4a and b). In contrast, the
addition of Bevacizumab, which targets VEGF, did not
affect the induction of CD133 expression (Fig. 4a and b).
The growth factor array performed revealed additional
interesting candidates, such as insulin-like growth factor-
binding proteins (IGFBPs) and specifically IGFBP-2, which
Fig. 3 bFGF in ECCM induces CD133 expression on BMP4-differentiated CD133− cells. a Growth factor array comparing control medium (left
panel) to ECCM (right panel). b, c Differentiation of G073 cells using 100 ng/ml BMP4 for 7 days and subsequent sorting of CD133− cells. Graphs
show % CD133+ cells 5 days after sorting, as determined by FACS ((b) n = 3, (c) left n = 2, right n = 3)
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has previously been implicated in GBM CSC biology [29].
Our results demonstrate that bFGF is capable of reverting
differentiated GBM cells to the CSC state in the experi-
mental model used. It should be noted, however, that
under different circumstances other proteins might fulfil
similar functions.
To determine whether bFGF also functionally reverts
differentiated GBM cells to the CSC state, BMP4-
differentiated CD133− cells were sorted in clonogenic
assays, either in control or bFGF-containing medium.
Indeed, bFGF was capable of promoting self-renewal
capacity yielding a clonogenic potential similar to that of
CD133+ GBM CSCs (Fig. 4c and e). G073 colonies that
grew out in medium containing bFGF entirely resembled
the parental undifferentiated population as judged by
CD133 expression (Fig. 4d).
Moreover, the expression of the differentiation
markers GFAP and βIII-tubulin was downregulated to
the level of the undifferentiated parental population in
G062 cells collected from the bFGF condition of the
clonogenic assay (Additional file 1: Figure S3D). Add-
itionally, cultures derived from BMP4-differentiated
CD133− G062 cells plated in bFGF containing medium
could recapitulate the same differentiation pattern as the
parental population, indicating their reversion to the
CSC state (Additional file 1: Figure S5).
Fig. 4 bFGF in ECCM is responsible for induction of CD133 expression and increases the clonogenic potential of BMP4-differentiated CD133− cells.
a BMP4-differentiated CD133− G073 cells were sorted and plated in control medium, ECCM, ECCM containing a bFGF neutralizing antibody (bFGF
nAb), or ECCM containing Bevacizumab. 5 days after sorting CD133 expression was reanalyzed by FACS (n = 3). b FACS plots corresponding to (a).
c The clonogenic potential of BMP4-differentiated CD133− G073 cells was assessed using clonogenic assays (n = 6). d CD133 expression of spheres
formed in (c) in the bFGF condition compared to the non-differentiated parental G073 spheroid culture (n = 2). e The clonogenic potential of
BMP4-differentiated CD133− G062 cells was assessed using limiting dilution assays (n = 5)
Fessler et al. Molecular Cancer  (2015) 14:157 Page 6 of 12
These results demonstrate that bFGF in ECCM is able
to phenotypically and functionally revert differentiated
GBM cells to CSC-like cells.
bFGF induces the reversion of O4+ oligodendrocyte-like
cells to the CSC state
The identification of differentiated cells after BMP4
treatment relies on the absence of the CSC marker
CD133. However, tumorigenic potential has also been
described for CD133− glioblastoma cells and various
other markers besides CD133 could identify populations
possessing CSC features as well [19–22, 24, 30]. Further-
more, the selection of differentiated cells by the absence
of a CSC marker does not exclude the presence of con-
cealed CSCs. In a population lacking classical CSC
markers these cryptic CSCs could be activated and
reconstitute the distinct cell fractions present in the
original population. To assess the reversion potential of
a culture consisting exclusively of differentiated cells we
made use of the cell surface oligodendrocyte marker O4.
G073 GBM CSCs could be effectively differentiated
toward the oligodendrocytic lineage using GF with-
drawal (− GFs) or addition of 2 % fetal calf serum
(+2 % FCS) for 7 days. In both conditions, cells dis-
played a differentiated morphology, gained O4 expres-
sion and downregulated the expression of Nestin
(Fig. 5a, Additional file 1: Figure S6A and Additional
file 1: Figure S7). Moreover, cells differentiated with
2 % FCS showed induction of GFAP and βIII-tubulin
expression (Additional file 1: Figure S6A). Differenti-
ation into distinct lineages was confirmed by qRT PCR
which also revealed the downregulation of the CSC
marker Musashi1 in both conditions and of OLIG2 in
cells differentiated with 2 % FCS (Fig. 5b and Additional
file 1: Figure S6B). As O4 is a cell surface marker detect-
able by FACS (Fig. 5c and Additional file 1: Figure S6C)
the differentiated oligodendrocyte-like tumor cells could
be sorted from the total population. Of note is the ap-
pearance of a CD133+O4+ population upon differenti-
ation. Since this population retains high expression of
the CSC marker CD133 it was not subject of the current
study; however, this population is intriguing and should
be characterized in future experiments.
For both differentiation conditions, CD133−O4+ cells
were sorted and plated in control medium, medium con-
taining bFGF, EGF, HGF, or VEGF for 5 days, after which
the presence of CD133−O4+ cells was analyzed. Also
under these conditions only bFGF was able to reduce
the amount of CD133−O4+ cells and to reinstall CD133
expression (Fig. 5d and Additional file 1: Figure S6D).
Further proof that reversal could be achieved with cells
differentiated using GF withdrawal was obtained by
stimulating CD133−O4+ cells that were sorted twice to
exclude contamination by missorting (Additional file 1:
Figure S8).
The reversal of CD133−O4+ cells is not only observed
phenotypically, but is also a functional conversion as
plating in bFGF-containing medium significantly in-
creased the clonogenic potential of these cells (Fig. 5e
and Additional file 1: Figure S6E). Analyzing the neuro-
spheres formed in the bFGF condition unveiled that
these cells reverted to a CSC-enriched population simi-
lar to the parental population according to CD133 and
O4 expression (Fig. 5f and Additional file 1: Figure S6F).
Moreover, cultures derived from these spheres displayed
the same differentiation pattern as the parental popula-
tion, indicating their reversion to the CSC state as deter-
mined by the acquisition of multilineage differentiation
potential (Additional file 1: Figure S9).
The same phenotypical and functional reversal of
CD133−O4+ cells induced by bFGF could be observed
when stimulating these cells with ECCM (Additional file 1:
Figure S10).
Taken together, these results demonstrate that differ-
entiated GBM cells can acquire CSC features and that
this process can be orchestrated by tMVECs.
Discussion
The unidirectional dogma states that CSCs give rise to
progenitor cells, which spawn transit amplifying cells
that proliferate quickly and differentiate into all progeny
found in a tumor. This hypothesis has lately been chal-
lenged by data supporting increased dynamics between
cell fractions.
Studies that demonstrate reversion of non-stem cells
to CSC-like cells depend on the use of frequently
debated CSC markers, such as CD133, to define the dif-
ferentiated population. However, these fractions do not
need to be completely devoid of CSCs, as CD133− cells
can be tumorigenic as well, spawning tumors when
transplanted into mice [13]. This can be explained by
contaminating CD133+ cells due to missorting or by the
existence of CSCs not defined by classical CSC markers.
In the case of GBM this could also be dependent on the
origin and/or subtype of the GBM tumor tested. To avoid
the presence of cryptic CSCs we therefore employed an
additional selection step and assessed reversion of GBM
cells forced into differentiation and of a culture consisting
solely of differentiated cells by sorting on the oligodendro-
cyte marker O4. Our results demonstrate that differenti-
ated GBM cells can acquire CSC features. Invariably this
implies that the cells maintain their CSC capacities, but
that these only become evident when the cells are placed
in the right microenvironmental conditions. In other
words differentiation as well as cancer stemness is in
part determined by a dominant microenvironment in
these cases.
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The analysis of the bFGF/ECCM-induced reversion in
vivo could not be addressed in this study as the lines
used herein did not display tumor growth following sub-
cutaneous injection. Thus, determining the impact of
this plasticity on therapy efficacy warrants further
investigation.
It is important to note, that distinct primary spher-
oid cultured GBM lines might differ in their behavior
based on origin and subtype affiliation. We described
previously that direct contact between tMVECs and
two GBM spheroid lines is necessary for induction of
proliferation and conditioned medium was not suffi-
cient to induce these effects [31]. Herein, using two
different spheroid-cultured GBM lines, conditioned
medium was capable to revert differentiated GBM
cells to the CSC state, indicating that secreted factors,
specifically bFGF, could provide the necessary input.
These differences could be explained by our cultures
Fig. 5 Differentiated GBM oligodendrocytes can be phenotypically and functionally redirected to the CSC state by bFGF. a Differentiation of G073
cells for 7 days by GF withdrawal (− GFs). Differentiation induces morphological changes and strong upregulation of the oligodendrocyte marker
O4 (scale bars 20 μm). b Analysis of differentiation and CSC markers by qRT PCR. Depicted is the fold change compared to cells plated in CSC
medium + GFs. 1 representative of 3 independent experiments is shown. c Differentiated GBM cells express the oligodendrocyte marker O4 on
their surface as determined by FACS. d CD133−O4+ cells were sorted and plated in the indicated condition. 5 days after sorting CD133 and O4
expression were reanalyzed by FACS (n = 3). e The clonogenic potential of differentiated CD133−O4+ cells was determined using clonogenic
assays (n = 4). f CD133 and O4 expression of spheres formed in (e) in the bFGF condition compared to the non-differentiated parental GBM
spheroid culture (n = 3)
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belonging to different subtypes of GBM tumors that
might have distinct requirements from their micro-
environment due to distinct sets of mutations [32, 33].
Conclusions
Previous studies have indicated the importance of GBM
CSCs in therapy refractoriness and tumor recurrence.
Based on these observations major efforts are invested
in eradicating the CSC population. Our findings suggest
that targeting the CSC fraction might not be sufficient
for effective treatment due to its complex cross-talk with
the microvasculature. Under the influence of their niche,
differentiated tumor cells could potentially acquire CSC
features and re-establish the CSC pool to maintain
tumor homeostasis. Thus, targeting CSCs through treat-
ment modalities intersecting the effects of the tumor
surrounding might be essential for developing effective
therapies.
Methods
Cell culture, ECCM and HCM preparation, and
differentiation of GBM cells
GBM cells and tMVECs were isolated from patient ma-
terial as described previously [31]. Human tissues were
obtained in accordance with the rules of the medical
ethical committee of the AMC. GBM spheroid cultures
were cultured as follows, further referred to as CSC
medium + growth factors (+ GFs): Advanced DMEM/
F12 (Gibco), supplemented with N2 supplement (Invi-
trogen), 2 mM L-glutamine, 0.15 % D-glucose (Sigma),
100 μM β-mercaptoethanol (Sigma), trace elements B
and C (Fisher Scientific), 5 mM HEPES (Life Technolo-
gies), 2 μg/ml heparin (Sigma), lipid mixture (Sigma),
10 μg/ml insulin (Sigma), 50 ng/ml human bFGF, and
20 ng/ml human EGF (Peprotech) in ultra-low attach-
ment flasks (Corning). Spheroids were dissociated with
accutase (Sigma) and replated in fresh medium twice
weekly. In all assays, control medium refers to CSC
medium without bFGF and EGF (CSC medium -GFs).
tMVECs were cultured in Endothelial Cell Medium
MV2 (Promocell) on gelatine-coated plates (Sigma) and
used between passage 2 and 8. HUVECs were cultured
in Endothelial Cell Medium MV2 (Promocell).
For preparation of ECCM and HCM, tMVECs or
HUVECs were grown to confluence, washed twice with
PBS, and CSC medium -GFs was added. After 24 h the
conditioned medium was collected, filter-sterilized and
stored at −20 °C.
To differentiate GBM CSCs, spheroid cultures were
brought to a single cell suspension using accutase and
washed twice with CSC medium -GFs. For adherent dif-
ferentiation as shown in Figs. 2a, 5a, Additional file 1:
Figure S3B, Additional file 1: Figure S5, Additional file 1:
Figure S6A, Additional file 1: Figure S7, and Additional
file 1: Figure S9 GBM cells were plated on laminin-
coated coverslips. For all other differentiation experi-
ments, GBM cells were differentiated in ultra-low
attachment flasks yielding the same differentiation pat-
tern as adherent differentiation (judged by qRT PCR, see
Figs. 2b, 5b, and Additional file 1: Figure S6B); in both
conditions for 7 days in CSC medium -GFs containing
100 ng/ml recombinant human BMP4 (+ BMP4; R&D),
CSC medium -GFs (GF withdrawal, − GFs), or CSC
medium -GFs containing 2 % non-heat inactivated FCS
(+2 % FCS). Medium was refreshed after 4 days.
Clonogenic assays
For clonogenic assays, cells were sorted in low-
attachment 96-well plates (Corning) at ascending clonal
densities. Fresh medium was added every 3 days and the
plates were scored 2 weeks after sorting. Wells contain-
ing spheroid structures were scored positive, empty wells
or wells containing individual cells were scored negative.
Clonogenic potential was determined using the Extreme
Limiting Dilution Analysis (ELDA) software: http://bioinf.-
wehi.edu.au/software/elda/. Data are represented as percent
clonogenic potential. Experiments for CD133+ cells in
control medium and CD133− cells in control medium and
ECCM or HCM were carried out simultaneously. Clono-
genic assays of differentiated cells were carried out inde-
pendently and the clonogenic potential of CD133+ cells
of the respective culture in control medium was in-
cluded in the graphs as reference but was not deter-
mined in the same experiment.
Immunostaining for FACS, cell sorting, ECCM, HCM and
GF treatment, and establishment of cultures upon
reversion
GBM spheroid cultures were dissociated into a single cell
suspension using accutase and filtering through a 40 μm
pore size cell strainer. CD133 (CD133/1 (AC133)-APC
(1:25; 130-090-826) or CD133/1 (AC133)-PE (1:100; 130-
080-801), Miltenyi Biotec), O4 (O4-APC (1:25), Miltenyi
Biotec 130-095-891), and SSEA-1 (1:250, R&D clone MC-
480 MAB2155) staining was performed in PBS + 1 % BSA.
For SSEA-1 staining, cells were subsequently incubated
with an anti-mouse IgM Alexa fluor 488 secondary anti-
body (1:500, Invitrogen A-21042) in PBS + 1 % BSA. To
exclude dead cells, propidium iodide was added to a final
concentration of 200 ng/ml. Cells were sorted using the
FACS Aria. Gating was performed using an unstained
control as reference, exemplary FACS plots are shown in
Additional file 1: Figure S1.
For analysis upon ECCM, HCM or GF treatment, cells
were sorted into tubes and directly after sorting plated
in low-attachment 24-well plates (Corning). Cells were
plated in CSC medium containing the GFs at the follow-
ing concentrations, if not otherwise indicated: 50 ng/ml
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bFGF, 20 ng/ml EGF, 25 ng/ml human HGF (R&D), and
10 ng/ml human VEGF-121 (Peprotech). After 24 and
72 h or 5 days, spheroids were dissociated with accutase,
stained for CD133 and/or O4 and analyzed on the FACS
Canto. Gating was performed using the control-treated
sample as a reference for the treated samples.
To block bFGF or VEGF in ECCM, a bFGF neutraliz-
ing antibody (bFGF nAb 25 μg/ml; clone bFM-1, Milli-
pore 05–117) or Bevacizumab (100 μg/ml; Avastin,
Roche), respectively, were added to ECCM and incu-
bated at 37 °C for 1 h before addition of the sorted cells.
To assess the differentiation potential of bFGF-reverted
cells, BMP4-differentiated CD133− G062 cells were plated
in bFGF-containing medium directly after sorting for
5 days. CD133−O4+ G073 cells differentiated using GF
withdrawal were sorted in clonogenic assays and spheres
that formed in the bFGF condition were collected 14 days
after sorting. After the 5 day (G062) or 14 day (G073) re-
version period in bFGF, spheres were dissociated to a sin-
gle cell suspension using accutase and grown up in CSC
medium+GFs. Once sufficient cells were obtained, the
cultures were subjected to adherent differentiation as de-
scribed above (Additional file 1: Figure S5 for G062 and
Additional file 1: Figure S9 for G073).
Immunofluorescence
GBM cells were plated on laminin-coated coverslips.
Cells were fixed using 4 % paraformaldehyde for 20 min
on ice. Blocking and primary antibody dilutions were
performed in PBS + 0.1 % Triton X-100 + 5 % normal
goat serum. Cells were incubated in primary antibody di-
lutions over night at 4 °C: anti-GFAP (1:250, Sigma
G9269), anti-βIII-tubulin (1:100, R&D MAB1195), anti-
O4-APC (1:25, Miltenyi Biotec 130-095-891), and anti-
Nestin (1:250, Santa Cruz 10C2 sc-23927). Secondary
antibody incubation was performed for 1 h at RT (anti-
rabbit IgG (H + L) Alexa fluor 488, anti-mouse IgG (H +
L) Alexa fluor 488, anti-mouse IgM Alexa fluor 488,
each 1:500, Invitrogen A-11034, A-11029, A-21042). For
washing steps PBS + 0.1 % Triton X-100 was used. DAPI
(Sigma) was included in the last washing step at a
concentration of 1 μg/ml. Slides were mounted using
ProLong Gold Antifade Reagent (Invitrogen). Pictures
were taken at a Zeiss Axiovert 200 M fluorescence
microscope at an oil magnification of 63x (scale bars
20 μm).
Quantitative real-time PCR
RNA was isolated using the Nucleospin RNA II Kit
(Macherey-Nagel). For qRT PCR, total RNA was reverse
transcribed to cDNA using Superscript III following the
manufacturer’s protocol (Invitrogen). qRT PCR was per-
formed using SYBR Green and a Roche Light Cycler 480
II in accordance with the manufacturer’s instructions.
All obtained values were normalized to the expression
of β-actin; normalization to 18S and B2M yielded simi-
lar results. The fold change as compared to GBM cells
grown in CSC medium + GFs is shown. Primer se-
quences: ACTB-forward: 5′-CAG AAG GAT TCC TAT
GTG GGC GA; ACTB-reverse 5′-TTC TCC ATG TCG
TCC CAG TTG GT. GFAP-forward: 5′- GGC AAA
AGC ACC AAA GAC GG; GFAP-reverse: 5′-GGC
GGC GTT CCA TTT ACA AT. TUBB3-forward: 5′-
CCT GAC AAT TTC ATC TTT GG TCA GAG T;
TUBB3-reverse: 5′-GCA CCA CAT CCA GGA CCG
AAT. OLIG1-forward: 5′-CAC AGC GGC CCG GAG
ACT T; OLIG1-reverse: 5′-CCT GTA GCC CAC CAG
CTC GTA GA. OLIG2-forward: 5′-CGC CAG AGC
CCG ATG ACC TT; OLIG2-reverse: 5′-GAC ACG
GTG CCC CCA GTG AA. Musashi1-forward: 5′-GAG
ACT GAC GCG CCC CAG CC; Musashi1-reverse: 5′-
CGC CTG GTC CAT GAA AGT GAC G.
Growth factor array
The growth factor array AAH-GF-1 (RayBiotech) was per-
formed on 3 independently derived ECCM samples and 1
control sample (CSC medium -GFs) following the manu-
facturer’s instructions. Detection was carried out using the
LAS4000 and the spot intensity was quantified using the
Odyssey V3.0 program. From each value of the ECCM the
value of the control medium was subtracted and the aver-
age of the duplicates was calculated. Displayed in the
graph are the raw intensities of the 3 different ECCM
samples taken together.
Statistical analyses
Data are presented as means + standard deviation.
P-values were determined using the unpaired two-tailed
Student’s t-test in GraphPad Prism 5 software. A P-value
of <0.05 was considered significant (* P < 0.05, ** P < 0.01,
*** P < 0.001).
Additional file
Additional file 1: Figure S2. ECCM and HCM increase the clonogenic
potential of non-stem GBM cells and increase the expression of CD133.
(A) Shown is the clonogenic potential of the SSEA-1− fraction of the
G073 culture in control medium or ECCM scored 2 weeks after sorting
(n = 2). (B) Indicated is the clonogenic potential of CD133− G408 cells in
control medium or ECCM and of CD133+ cells in control medium, scored
2 weeks after sorting (n = 2). (C) G408 CD133− cells were plated in control
medium or ECCM directly after sorting. Quantification and FACS profiles
depict CD133 expression 72 h after sorting (n = 2). (D) Displayed is the
clonogenic potential of CD133− G602 cells in control medium or HCM
and of CD133+ cells in control medium, scored 2 weeks after sorting (n = 2).
(E) G062 CD133− cells were plated in control medium or HCM directly after
sorting. Quantification and FACS profiles depict CD133 expression 72 h after
sorting (n = 4). Figure S3. BMP4 differentiation leads to downregulation of
SSEA-1 and Nestin and to a decreased clonogenic potential which can be
reverted by ECCM and bFGF. (A) Representative FACS plots of SSEA-1 stain-
ing on BMP4-differentiated G073 cells and the parental population (+ GFs).
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The bar plot shows % SSEA-1+ cells upon BMP4-induced differentiation
(+ BMP4) compared to the parental population (+ GFs) (n =5). (B) 7 day
BMP4 differentiation leads to the downregulation of Nestin expression
in G073 (left) and G062 (right) cells as compared to cells plated in CSC
medium+GFs (scale bars 20 μm; n= 2). (C) The clonogenic potential of
BMP4-differentiated G073 (left) and G062 (right) cells upon plating in control
medium, ECCM or medium containing bFGF was determined using clono-
genic assays (n= 2). (D) GFAP and βIII-tubulin expression in 7 day BMP4-
differentiated G062 cells and in spheres formed in the bFGF condition
shown in (C). Depicted is the fold change compared to cells plated in
CSC medium + GFs. 1 representative of 3 independent experiments is
shown. Figure S4. bFGF is secreted by tMVECs and induces CD133
expression on BMP4-differentiated CD133− cells. (A) Quantification of
the growth factor arrays shown in Fig. 3a. Graph depicts quantification
of 3 growth factor arrays using different batches of ECCM. Shown is the
intensity of each spot minus the intensity of the respective spot on the
control array. (B) BMP4-differentiated CD133− G062 cells were plated in
the indicated condition directly after sorting. 5 days after sorting CD133
expression was analyzed by FACS (n = 4). Figure S5. Neurospheres
derived from CD133− G062 cells stimulated with bFGF recapitulate the
differentiation pattern of the parental population. (A) Plating G062 cells
for 7 days in BMP4 containing medium leads to morphological differen-
tiation as well as upregulation of GFAP, indicating the differentiation
to the astrocytic lineage as compared to cells plated in GF-containing
medium (scale bars 20 μm). (B) A culture derived from BMP4-differentiated
CD133− G062 cells stimulated with bFGF after sorting was plated in
medium containing GFs or BMP4. These cells displayed the same differenti-
ation pattern as the parental population, demonstrated by the expression of
GFAP and βIII-tubulin (n = 2, scale bars 20 μm). Figure S6. Differentiated
GBM oligodendrocytes can be phenotypically and functionally redirected to
the CSC state by bFGF. (A) Differentiation for 7 days by addition of 2 % FCS
(+2 % FCS). G073 cells differentiate into all 3 lineages, indicated by the
expression of GFAP, βIII-tubulin, and O4 (scale bars 20 μm). (B) Analysis of
differentiation and CSC markers by qRT PCR. Depicted is the fold change
compared to cells plated in CSC medium + GFs. 1 representative of 3
independent experiments is shown. (C) Differentiated GBM cells express
the oligodendrocyte marker O4 on their surface as determined by FACS.
(D) CD133−O4+ cells were sorted and plated in the indicated condition.
5 days after sorting CD133 and O4 expression were analyzed by FACS
(n = 3). (E) The clonogenic potential of differentiated CD133−O4+ cells
was determined using clonogenic assays (n = 4). (F) CD133 and O4
expression of spheres formed in (E) in the bFGF condition compared to
the non-differentiated parental GBM spheroid culture (n = 2). Figure S7.
Nestin expression is downregulated upon differentiation in G073 cells. 7
day differentiation of G073 cells using GF withdrawal (−GF) or addition of
2 % FCS (+2 % FCS) leads to downregulation of Nestin expression as
compared to cells plated in CSC medium + GFs (scale bars 20 μm; n = 2).
Figure S8. Gain of CD133 and loss of O4 expression on differentiated
cells induced by bFGF is not due to expansion of a contaminating CD133
+O4− fraction. (A) Differentiation and sorting of G073 cells as described in
(Fig. 5 and Additional file 1: Figure S6). The purity of the sort was ana-
lyzed immediately afterwards by FACS. (B) After differentiation using GF
withdrawal, CD133−O4+ cells were sorted twice and plated in low
adherence for 5 days. Subsequently the expression of CD133 and O4 was
analyzed by FACS. Induction of CD133 and loss of O4 were as efficient as
after a single sort (n = 1). Figure S9. Neurospheres derived from CD133−O4+
cells stimulated with bFGF recapitulate the differentiation pattern of the
parental population. Cultures derived from G073 spheres that formed in a
clonogenic assay in bFGF-containing medium (as described in Fig. 5e)
were differentiated using the depicted conditions. These cells displayed
the same differentiation pattern as the parental population, demon-
strated by the expression of GFAP, βIII-tubulin, and O4 (n = 3; scale bars
20 μm). Figure S10. Differentiated GBM oligodendrocytes can be
phenotypically and functionally redirected to the CSC state by ECCM.
(A,B) Differentiation of G073 cells for 7 days by GF withdrawal (− GFs) (A)
or addition of 2 % FCS (B) and subsequent sorting of CD133−O4+ cells in
the indicated condition. 5 days after sorting CD133 and O4 expression
were reanalyzed by FACS (n = 4 for - GF and n = 2 for + 2 % FCS) (C,D)
The clonogenic potential of differentiated CD133−O4+ cells was deter-
mined using clonogenic assays (n = 2 for - GF and n = 3 for + 2 % FCS).
Figure S1. Gating on cell populations for sorting was performed using
an unstained control as reference. (A-C) Shown are exemplary FACS plots
for the identification of (A) the CD133−O4+ (− GF and + 2 % FCS) and
CD133− (+ BMP4) fraction of G073 cells, (B) the SSEA-1− population of
G073 cells, and (C) the CD133− fraction of BMP4-differentiated G062 cells.
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